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Background: Local hyperthermia of tumor in conjunction with chemotherapy is a promising strategy for cancer
treatment. The aim of this study was to evaluate the efficacy of intratumoral delivery of clinically approved
magnetic nanoparticles (MNPs) conjugated with doxorubicin to simultaneously induce magnetic hyperthermia and
drug delivery in a hepatocellular carcinoma (HCC) model.
Materials and methods: HCC cells expressing luciferase were implanted into the flank of BALB/c-nu mice (n = 19).
When the tumor diameter reached 7–8 mm, the animals were divided into four groups according to the injected
agents: group A (normal saline, n = 4), group B (doxorubicin, n = 5), group C (MNP, n = 5), and group D (MNP/doxorubicin
complex, n = 5). Animals were exposed to an alternating magnetic field (AMF) to receive magnetic hyperthermia, and
intratumoral temperature changes were measured.
Bioluminescence imagings (BLIs) were performed before treatment and at 3, 7, and 14 days after treatment to measure
the tumoral activities. The relative signal intensity (RSI) of each tumor was calculated by dividing the BLI signal at each
time point by the value measured before treatment. At day 14 post-treatment, all tumor tissues were harvested to assess
the apoptosis rates by pathological examination.
Results: The rise in temperature of the tumors was 1.88 ± 0.21°C in group A, 0.96 ± 1.05°C in B, 7.93 ± 1.99°C in C, and
8.95 ± 1.31°C in D. The RSI of the tumors at day 14 post-treatment was significantly lower in group D (0.31 ± 0.20) than in
group A (2.23 ± 1.14), B (0.94 ± 0.47), and C (1.02 ± 0.21). The apoptosis rates of the tumors were 11.52 ± 3.10% in group A,
23.0 ± 7.68% in B, 25.4 ± 3.36% in C, and 39.0 ± 13.2% in D, respectively.
Conclusions: The intratumoral injection of ferucarbotran conjugated with doxorubicin shows an improved therapeutic
effect compared with doxorubicin or ferucarbotran alone when the complex is injected into HCC tissues exposed to AMF
for magnetic hyperthermia. This strategy of combining doxorubicin and MNP-induced magnetic hyperthermia exhibits a
synergic effect on inhibiting tumor growth in an HCC model.
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Hepatocellular carcinoma (HCC) remains the fifth most
common cancer as well as the third leading cause of can-
cer mortality worldwide [1]. Current therapeutic options,
including surgical resection, radiotherapy, and chemother-
apy, have been unsatisfactory in most patients. Although
surgical resection has been recognized the most effective
treatment for HCC, its efficacy is limited to the minority
of patients who have early stage disease. Patients with
underlying liver disease, unsuitability for resection, or little
organ availability for transplantation are not candidates
for surgery [2].
Hyperthermia is a very promising cancer treatment
based on the hypothesis that cancerous cells are more sen-
sitive to an increase in the tissue temperature than normal
cells [3]. In recent years, various hyperthermic ablation
therapies such as radiofrequency ablation, microwave abla-
tion, and high intensity focused ultrasound have been
widely introduced especially for liver cancer. Another strat-
egy for heat induction in tumor is magnetic hyperthermia.
When exposed to a high-frequency magnetic field, mag-
netic nanoparticles (MNPs) generate heat through the
oscillation of their magnetic moment due to Neel and
Brownian relaxations [4]. Direct injection of MNPs into
solid tumors, followed by exposure of tumors to an alter-
nating magnetic field (AMF), has been shown to induce
controlled heating at the target tumors, which leads to
tumor regression [5]. After exposure of tumor-bearing
organs to AMF, the induced heat that raises the tissue
temperature to approximately 41–47°C is known to alter
the function of many structural and enzymatic proteins
within cells, which in turn arrests cell growth and
differentiation and eventually induces apoptosis [6,7]. This
particle-induced magnetic heating can be controlled by
accurate and localized delivery of the MNPs to the target
lesions, and has been under several clinical trials [8].
Additionally, MNPs have been investigated as drug delivery
systems to improve the efficacy of drugs. The loading of
drugs to MNPs can be achieved either by conjugating the
therapeutic agents onto the surface of the MNPs or by co-
encapsulating the drug molecules along with MNPs within
the coating material envelope [9]. Once at the target site,
MNPs can stimulate drug uptake within cancer cells by
locally providing high extracellular concentrations of the
drug or by direct action on the permeability of cell mem-
branes [10]. Most of MNPs are not approved for use in
humans because their safety and toxicity have not been
clearly documented. However, ferucarbotran (Resovist;
Bayer Schering Pharma AG, Leverkusen, Germany) is a
clinically-approved superparamagnetic iron oxide nanopar-
ticle that has been developed for contrast-enhanced MRI
of the liver [11]. Local hyperthermia of tumor tissue in
conjunction with chemotherapy has been demonstrated to
significantly enhance antitumor efficacy [12]. Here, wedesigned a complex made with both Resovist, an MNP ap-
proved for clinical use in humans, and doxorubicin to
combine the magnetic control of heating and drug delivery
into one treatment. We expected that this complex would
enhance the synergistic efficacy and yield substantial prom-
ise for a highly efficient therapeutic strategy in HCC. The
in vivo antitumor effect was evaluated by bioluminescence
imaging (BLI), which measures the luciferase-expressing
tumor cells’ activity, throughout the follow-up period.
Materials and methods
Preparation of the Resovist/doxorubicin complex
Doxorubicin was loaded on the surface of Resovist via
an ionic interaction as previously described [13]. Reso-
vist was loaded with doxorubicin through ionic interac-
tions between anionically charged carboxydextran
coating layer of Resovist and positively charged amino
groups of doxorubicin. Predetermined amount of doxo-
rubicin (0.2 mg, Adriamycin; Ildong Pharmaceutical,
Seoul, Republic of Korea) was dissolved in 4 mL deion-
ized water, and the aqueous solution was transferred to
a 250-mL round-bottom flask. Diluted (1.38 Fe mg/mL)
Resovist in 4 mL deionized water was added dropwise
using a syringe pump at a rate of 0.1 mL/min, and the
reaction mixture was vigorously stirred for 8 hours.
Loading efficiency of doxorubicin was 100% and ultra-
violet–visible spectroscopy at 480 nm confirmed that
there was not any doxorubicin left in the aqueous solu-
tion. The Resovist/doxorubicin complex was obtained as a
solid after freeze-drying and the diameter of the complex
before and after the freeze-drying was not so different
based on DLS data. The concentration of doxorubicin in
the complex was adjusted to 1 mg/ml. The release profile
of doxorubicin from the complex was evaluated by the
dialysis method. Two milliliters aqueous solution of the
complex conjugated to doxorubicin (2 mg) was transferred
into a dialysis membrane with a molecular weight cutoff
of 1 K and dialyzed against deionized water (20 mL). The
temperature of the medium was changed to either 37°C or
60°C at a predetermined time, and an aliquot was sampled
at 1, 2, 3, 4, 5, 6, 18, 42 and 66 hours. The amount of re-
leased doxorubicin was measured by ultraviolet–visible
spectroscopy at 480 nm.
To test whether the conjugation process would affect
the MR imaging of Resovist, we measured the MR relax-
ivity of the Resovist/doxorubicin complex, which was
compared with that of Resovist. The particles were seri-
ally diluted from a concentration of 0.15 mM in an agar-
ose phantom designed for relaxivity measurements,
which was done using a 3-T MR scanner (Tim Trio;
Siemens Healthcare, Erlangen, Germany). Fast spin echo
T2-weighted MR images of the phantom were acquired
using the following parameters: relaxation time = 5000 ms,
echo times = 16, 32, 48, 64, 20, 40, 60, 80, 50, or 100 ms,
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mm2, matrix = 256×117, slice thickness/gap = 1.4 mm/
1.8 mm, and NEX= 1.
Preparation of the animal model
Hep3B, a human HCC cell-line, was transduced with a
retroviral vector containing the firefly luciferase (luc) re-
porter gene, and a highly expressing reporter clone was
isolated to establish Hep3B + luc cells. Hep3B + luc cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Welgene, Seoul, Korea) supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (GIBCO, Seoul,
Korea). All animal procedures were performed according
to our Institutional Animal Care and Use Committee-
approved protocol (SNUH-IACUC #12-0015). Male BALB/
c-nude mice (n = 19), aged 6 weeks and weighing 20–25 g,
were used for this study. Hep3B + luc cells were suspended
at 1×106 cells/0.1 ml in serum-free DMEM and subcutane-
ously injected into the right flanks of the animals. Two
weeks after tumor implantation, when the tumor diameter
reached approximately 7–8 mm in diameter, the animals
were evenly divided into 4 groups according to the injected
agents: group A (n = 4) injected with normal saline, group
B (n = 5) with doxorubicin (4 mg/kg), group C (n = 5) with
Resovist (Fe 111.6 mg/kg), and group D (n = 5) with the
Resovist/doxorubicin complex (Fe 111.6 mg/kg, doxorubi-
cin 4 mg/kg). As the lethal dose of ferucarbotran solution
in rodents was reported to be in excess of 558 mg Fe/kg
[14], our dosage of Resovist was within the safe range. All
therapeutic agents were dissolved in the same volume of sa-
line (0.1 ml) and injected directly into the core of tumors.
Magnetic hyperthermia
The animals were fully anesthetized by intraperitoneal ad-
ministration of 12 mg/kg tiletamine-zolazepam (Zoletil 50;
Virbac, Carros, France) and 0.75 mg/kg xylazine hydro-
chloride (Rompun; Bayer, Seoul, South Korea). The ani-
mals were then placed in the center of AC coil to generate
AMF (Figure 1). An original device was connected to the
coil (width 30 cm, length 30 cm) and cooling unit, which
was cooled continuously by flowing water by the unit (Re-
circulating coolers HX-45H; Jeiotech, Daejeon-si, Korea).
A high-frequency generator worked at a current of 155 Oe
at a frequency of 100 kHz for magnetic hyperthermia. A
20-gauge venipuncture catheter (BD Angiocath Plus with
intravenous catheter; Becton Dickinson Korea, Gumi-si,
Korea) was inserted into each tumor so that an electronic
thermometer (Luxtron m3300 Biomedical Lab Kit Fluorop-
tic Thermometer; LumaSense Technologies, Santa Clara,
CA) could be passed through the catheter to measure the
core temperature of the tumor during the procedure. To
evaluate the selectivity of heating during the hyperthermia
treatment, rectal temperatures were simultaneously mea-
sured in a same manner as described above.Bioluminescence imaging for the in vivo evaluation of
therapeutic responses
Bioluminescence imaging (BLI) was performed using
the IVIS lumina II (PerkinElmer, Waltham, MA). Mice
were anesthetized with 1% isoflurane (Ifran, Hana Pharm.
Co, Seoul, Korea) in room air. D-luciferin (Caliper Life
Sciences, Hopkinton, MA) dissolved in PBS (1.5 mg lucif-
erin/100ul PBS) was injected intraperitoneally at a dose of
150 mg luciferin/kg, and serial images were acquired with
an exposure time of 30 sec, an f/stop of 1, and pixel binning
at 8 over 20 minutes to determine the peak biolumines-
cence. Subsequently, regions of interest (ROIs) of equal size
were drawn within the tumor to measure average radiance
(expressed as photons/s/cm2/sr). The BLIs were performed
just prior to treatment to obtain the baseline value and at 3,
7 and 14 days after treatment. By using Living Image® 4.2
software (Caliper Life Sciences, Hopkinton, MA), we mea-
sured the peak total tumor bioluminescent signal through
standardized ROIs. To ensure longitudinal comparability
of the serial measurements, we calculated the relative sig-
nal intensities (RSIs) by normalizing each measured peak
total tumor bioluminescent signal in a mouse with the sig-
nal at baseline as follows: [RSI at a time-point = (peak sig-
nal intensity at a time-point/peak signal intensity at
baseline)] [15].
Histopathological evaluations
All animals were euthanized at day 14 after treatment. The
extracted tumors were perfused with PBS, fixed in 4% para-
formaldehyde solution, and embedded in paraffin. The tu-
mors were sectioned at a thickness of 4 μm at the largest
tumor area. Hematoxylin and eosin (H&E) staining was per-
formed for a general inspection of the pathologic specimens.
Prussian blue staining was added to visualize the injected
iron particle distribution within the tumor tissues. To evalu-
ate the extent of tumor apoptosis for validating in vivo BLI
results, a terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay was performed with a commer-
cial kit (Roche, Mannheim, Germany). TUNEL staining is a
method to stain cells exhibiting apoptotic or non-apoptotic
DNA damage (i.e., DNA fragmentation), such as necrotic
cell death [4,16]. The percent area of apoptosis was calcu-
lated using NIH Image J software (NIH, Bethesda, MD).
After drawing a free-hand ROI to completely cover the
tumor, the number of pixels in the tumor area was counted.
Within the selected tumor area, the number of pixels corre-
sponding to the apoptosis area stained with TUNEL was
also counted. The percent area of apoptosis (%) was calcu-
lated by dividing the area of the TUNEL-stained area
(pixels) by the area of the total tumor (pixels).
Doxorubicin fluorescence microscopy
Fourteen days after treatment, some of the extracted
tumor tissues were immediately cryosectioned at a
Figure 1 Photograph of hyperthermia treatment. A) A tumor-bearing mouse is placed in the center of the hyperthermia device generating
AMF. B) A thermo-sensor is inserted into the tumor by way of a venipuncture catheter to measure temperature changes during the treatment.
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at −70°C. After washing the tissues, the cover slips
were mounted onto glass slides using mounting
medium (Faramount aqueous mounting medium;
Dako, Carpinteria, CA). On the slides, the distribution of
doxorubicin over the tumor area was observed under a
fluorescence microscope (Leica DM5500B, Leica, Wetzlar,
Germany) using excitation and emission wavelengths of
520 and 580 nm, respectively. The fluorescence images
were acquired using the following parameters: magnifica-
tion = 200×, BF: EX14 Gain 1.1 Intensity 1 gamma 45, and
FLU: EX 656 Gain 4 Intensity 5 gamma 20.
Statistical analyses
All data are expressed as means ± standard deviation
(SD), and the data processing and analysis were performed
using SPSS version 16.0 (SPSS, Inc., an IBM Company,
Chicago, IL). The nonparametric analysis was conducted
by the Mann–Whitney test to compare the temperature
changes in tumors, BLIs values, and apoptosis rates be-
tween the experimental groups. A p-value of less than 0.05
was considered statistically significant.
Results
The characterization of the Resovist/doxorubicin complex
The size of Resovist measured by dynamic light scattering
was 70.3 ± 31.5 nm and increased to 88.4 ± 39.5 nm when
doxorubicin was conjugated on the surface (Figure 2). The
amount of doxorubicin was adjusted to be 2 mg/mL at the
final administration for our study. Because the amount of
doxorubicin was not a maximized value, the loading effi-
ciency was 100%. The Resovist/doxorubicin complex was
freeze-dried and stored as a solid. Redispersion of the
complex by vortexing and/or sonication resulted in a simi-
lar size distribution reproducibly without any difficulties.When measuring the T2 relaxivities of the particles, the r2
values of Resovist and the Resovist/doxorubicin com-
plex were 295.0 s−1 mM−1 and 265.7 s−1 mM−1, respect-
ively (Figure 3).
Figure 4 summarizes the release pattern of doxorubicin
from the complex. The driving force for the doxorubicin
conjugation is an ionic interaction, which is known to
weaken as the temperature increases. The release test was
performed at two different temperature, 37°C and 60°C,
with a predetermined time profile to mimic the condition
of hyperthermal therapy. As expected, sustained release of
doxorubicin was observed at 37°C, whereas the release
was accelerated at the elevated temperature.
Tumor temperature measurement
The tumor temperature in group C and D rapidly in-
creased to approximately 42°C within 5 minutes and then
remained stable for 20 minutes, whereas in group A and
B did not increased significantly (Figure 5A). The aver-
age values of tumor temperature change 25 minutes
after initiation of hyperthermia were 1.88 ± 0.21°C in
group A, 0.96 ± 1.05°C in group B, 7.93 ± 1.99°C in group C,
and 8.95 ± 1.31°C in group D (Figure 5B). Group C and D
exhibited a significantly higher temperature in the tumors
than group A or B (p < 0.05). The exact p-values obtained
from comparisons between groups are summarized in
Table 1. The rectal temperatures in all groups remained
stable near the baseline values during the treatment.
Bioluminescence imaging findings
In group A receiving normal saline for control, the RSI of
BLI increased continuously over the follow-up period
reflecting active tumor growth (2.23 ± 1.14). In group B,
the RSI of BLI slightly decreased gradually until day 14
post-treatment (0.94 ± 0.47), which suggests that the
Figure 2 Preparation and characterization of Resovist-doxorubicin complex.
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(Figure 6A, B).In group C, the RSI of the BLI rapidly
dropped 3 days after treatment and rebounded to near-
baseline value at day 14 post-treatment(1.02 ± 0.21),
suggesting complete recovery of tumoral activities at
the later stage of treatment (Figure 6A, B). However, the
RSI of BLI in group D dropped 3 days after treatment as
in group C and exhibited minimal recovery until day 14
post-treatment (0.31 ± 0.20) (Figure 6A, B).The Mann–
Whitney test performed for the BLI values at day 14
post-treatment revealed that the RSI of BLI in group D
was significantly lower than the other groups (all p-
values < 0.05) (Figure 6C). The exact p-values obtained
between groups are summarized in Table 1. No mouseFigure 3 Measurement of MR relaxivities. A) T2-weighted MR image of
transverse relaxation times (1/T2) vs. Fe concentration. The slopes indicateexhibited signs of debilitation in any of the groups
through the follow-up period.
Histopathological findings
TUNEL assay of the tumor tissues obtained at day 14 by re-
vealed that the apoptosis/necrosis rate in group D was
higher (39.0 ± 13.2%) than group A (11.52 ± 3.10%), B (25.4
± 3.36%), and C (23.0 ± 7.68%) (Figure 7). Therefore, the
Resovist/doxorubicin complex showed significantly more
cell death than doxorubicin or Resovist monotherapy (all p-
values < 0.05).The exact p-values obtained between groups
are summarized in Table 1. Prussian blue staining of the
consecutive section demonstrated multiple iron deposits
within the tumor tissues in groups C and D (Figure 8).the phantom for relaxivity measurement. B) Plot of the inverse
the specific relaxivity value (r2).
Figure 4 The in vitro release pattern of doxorubicin from the Resovist-doxorubicin complex.
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On fluorescence microscopic examination, group D exhib-
ited higher fluorescence intensity from doxorubicin in the
tumor tissues, which significantly overlapped the area with
the iron particles. By contrast, group B exhibited minimalFigure 5 The temperature changes of the tumors. A) Plot of the tempe
group B, green: group C, purple: group D). B) The mean temperature chan
standard deviations (*P < 0.05, compared to group A).fluorescence from doxorubicin (Figure 9). This result sug-
gests that the Resovist/doxorubicin complex could release
doxorubicin into the tumor tissues in a controlled manner
for a longer period than free doxorubicin and allowed per-
sistent drug accumulation.rature change curve during heating versus time (blue: group A, red:
ges of the tumors (t/t0) during treatment. The error bars represent the
Table 1 Comparisons of the temperature changes in
tumor, RSIs of BLI at day 14 post-treatment, and







Temperature changes 0.009* 0.009* 0.465
RSIs of BLI 0.834 0.047** 0.009*
Apoptosis rates 0.675 0.028** 0.008*
Each number in the table indicates a p-value obtained by Mann–Whitney test.
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MNPs have gained considerable interest for biomedical
applications over the past two decades [17]. Although
this excitement has been driven mostly by the success of
MNPs as T2 MR contrast agents [18], the recent investi-
gative trend has turned toward therapy with respect to
cancer. The key properties of MNPs for cancer include
drug delivery, magnetic hyperthermia, and MR imaging.
Thus, MNPs contribute both diagnostic and therapeutic
accomplishments in a single system.
Drug delivery systems are required to ensure that the
drug is properly delivered to target, and nanoparticle-
based drug delivery systems have been developed as po-
tential drug carriers for decades. Because the large
surface-to-volume ratio of MNPs, like other nano-carriers,
enables a high loading of various functional ligands on a
single platform, marked attention has been paid to theirFigure 6 Bioluminescence imaging (BLI). A) Representative BLI obtained
B) Relative signal intensity [RSI] of BLI over the follow-up period. C) A grap
after treatment (*P < 0.05, compared to group A).use as drug delivery vehicles. In our study, the loading effi-
ciency of doxorubicin was 100%. The ultraviolet–visible
spectroscopy at 480 nm confirmed that there was not any
doxorubicin left in the aqueous solution, which led to a
conclusion that washing step to remove unbound doxo-
rubicin was not required.
MNP coatings provide anchor points to which drug
molecules can be coupled and have incorporated trad-
itional small molecules such as doxorubicin for cancer
therapy [19], as in our study. Resovist is coated with car-
boxydextran, to which doxorubicin was linked via ionic
complexation by dropping synthesis with an average size
of less than 100 nm in our study (Figure 2). When Reso-
vist/doxorubicin complex reached tumor tissues after
intratumoral injection, the complex was able to carry
higher concentrations and exhibited prolonged release of
doxorubicin in the tumor tissues as measured by fluores-
cence microscopy (Figure 9).
Magnetic hyperthermia can be used to selectively kill
tumor cells via increases in tissue temperature [4]. When
MNPs accumulating at the tumor site are exposed to
AMF, MNPs absorb this energy and convert it into heat
owing to the relaxation of the rotating magnetic moments
induced by the AC field. Tumors are usually heated to the
temperature range of 41–47°C, and cancer tissues exhibit
higher heat sensitivity than normal tissues [20]. It also has
been believed that the drug delivery to target could bein each group by the IVIS lumina II (PerkinElmer, Waltham, MA).
h demonstrated the relative signal intensity [RSI] of BLI at 14 days
Figure 7 Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assays to measure apoptotic cell death by light
microscopy. A) TUNEL-positive (brown color) cells with apoptotic morphology were observed in all groups (x200). B) A graph demonstrating the
apoptosis/necrosis rates in all groups by image J software (*P < 0.05, compared to group A).
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tion and diffusion in tissues, increasing cell uptake of the
drug, tumor blood flow and vascular permeability [21]. In
our study, Resovist or the Resovist/doxorubicin complex
also induced temperature increases to approximately 41°C
(Figure 5A). Although magnetic hyperthermia is a promis-
ing cancer therapy, the risk of local overheating (and thus
damage to normal tissues) remains the major concern, as
in other clinical hyperthermia therapies such as radiofre-
quency ablation or high-intensity focused ultrasound. To
overcome these challenges, the MNPs should be accur-
ately delivered only to the target tumors, the temperature
of which can be easily controlled by adjusting the MNP
concentration delivered and the proper manipulation ofthe magnetic field strength. Furthermore, some thermally
responsive agents that aid in specific nanoparticle reten-
tion within the tumor can reduce the diffusion of MNPs
to healthy tissues adjacent to the tumor [22]. One of the
advantages of magnetic hyperthermia over other clinical
hyperthermic treatments is that one is able to repeat the
treatment in a short interval without additional invasive
procedures. MR scans can predict the distribution of the
MNPs to prevent unwanted heating of the normal tissues.
If the nanoparticles accurately cover the tumor tissues on
a short-term follow-up MR, magnetic hyperthermia is able
to be repeated without causing major side effects. Further-
more, local overheating may be avoided by selecting parti-
cles with a low maximal achievable temperature while
Figure 8 Histopathological analyses of the tumor tissues by light microscopy. Hematoxylin and eosin staining (left), Prussian blue staining
(middle), and TUNEL staining (right) of a tumor treated with the Resovist/doxorubicin complex (x100).
Jeon et al. Journal of Experimental & Clinical Cancer Research 2014, 33:57 Page 9 of 11
http://www.jeccr.com/content/33/1/57preserving the magnetization for efficient heating [23].
Among the many MNPs, Resovist is clinically approved
for contrast-enhanced MR in human [11] and was previ-
ously reported to generate effective heat in AMF [14].
Choosing an MNP already approved for clinical use was
our main strategy to facilitate early translation of our study
into clinical practice. Though Resovist is not marketed as
a MR contrast agent due to the emergence of a novel MR
contrast, the result in our study may open a new potential
other than MR contrast for its clinical use.
Ferucarbotran consists mainly of a hydrophilic col-
loidal solution of superparamagnetic iron oxide coated
with carboxydextran. It is a complex composed of ultra-
fine (7nmdiameter) magnetite particles and alkali-
treated dextran [4]. The tumor cells in the center of the
tumor tissues are not sensitive to chemotherapy due to
hypoxia but are sensitive to hyperthermia due to low
pH value, whereas the tumor cells in the tumor periph-
ery are sensitive to chemotherapy [12,24]. Hyperther-
mia, when it is applied to specific lesions, produces
increased perfusion to the diseased area and makes theFigure 9 Fluorescence microscopy images. Representative fluorescence
Group D exhibits higher doxorubicin fluorescence signals (red spots) thancells more permeable for better cellular uptake of
agents. Therefore, when the hyperthermia is combined
with chemotherapy for cancer, the heat that is generated
in the targeted tumor can induce higher levels of drug
accumulation in the tumor cells by the same mechan-
ism described above. Doxorubicin is visualized by fluor-
escence microscopy with excitation wavelength at
480 nm [25], which enables us to detect the doxorubicin
deposits in the tumor tissues. In our study, the fluores-
cence intensity was much higher in group D than in
group B, suggesting an increased and long-lasting up-
take of doxorubicin into the cells in group D (Figure 9).
Although doxorubicin has been widely used as single
agent or in combination with other anticancer drugs for
HCC [26], the drug produces many side effects derived
from its nonspecific uptake into healthy normal tissues
[27]. Therefore, recent studies have focused on the devel-
opment of administration routes for doxorubicin to in-
crease tissue selectivity [28]. Local administration of the
agent is one promising approach with the advantage
of reaching high concentrations at the target site moreimages of group B (left), group C (middle), and group D (right).
the other two groups.
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injected the therapeutic agents directly into the tumor by
the naked eye in our study, we are designing a future pro-
ject to create an orthotopic liver tumor in which we can
inject the therapeutic agents under image guidance using
ultrasonography. Our future experiment using an orthoto-
pic model is expected to provide more translatable data.
In this study, we performed BLI for in vivo monitoring of
the therapeutic effect. BLI requires a reporter construct
produce luciferase, an enzyme that provides imaging con-
trast by light emission resulting from luciferase-catalyzed
conversion of D-luciferin to oxyluciferin in small animals
[30]. Our data demonstrated that the tumor activity signals
in group D were significantly lower than those in groups B
and C at the end of follow-up period (Figure 6). Fourteen
days after treatment, the BLI signal intensity reverted to
31% of the baseline value in group D, whereas those of
groups B and C reverted to 90% and 113%, respectively. Al-
though hyperthermia applied in the absence of doxorubicin
exhibited a marked reduction in the BLI signal in the early
stages of treatment, the signal was fully recovered at day
14 post-treatment. However, combination therapy using
the Resovist/doxorubicin complex demonstrated a BLI
signal that did not rebound during the 14 days post-
treatment, representing persistent antitumor efficacy.
In conclusion, the biomedical application of nanomater-
ials is gradually increasing and is a challenging area for fu-
ture research. Despite the a significant progress with
respect to MNP platforms, regulatory approval for use in
humans requires extensive safety studies of newly devel-
oped particles. To overcome challenges for clinical transla-
tion, we proposed an innovative approach that exploits
MNPs conjugated with an anti-cancer drug to achieve effi-
cient drug release and thermotherapy in a single platform
composed of agents already approved for use in humans.
We determined that combination therapy using the Reso-
vist/doxorubicin complex could enhance anti-tumor effi-
cacy in an HCC model by simultaneous induction of
hyperthermia and drug delivery. This system enables a
multi-modal therapy that can provide an efficient strat-
egy against cancer based on both physical (heat) and
chemical (drug) properties. We hope that our results
will help to facilitate the clinical translation of MNPs
for their future development.
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